Person:
Navarro García, Federico

Profile Picture
First Name
Federico
Last Name
Navarro García
URI
https://hdl.handle.net/20.500.14352/77657
Affiliation
Universidad Complutense de Madrid
Faculty / Institute
Farmacia
Department
Microbiología y Parasitología
Area
Microbiología
Identifiers
UCM identifierORCIDScopus Author IDWeb of Science ResearcherIDDialnet IDGoogle Scholar ID

Filters

20221
Reset filters

Settings

Author: Alonso González, Mario × Subject: 615.4 ×

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    Limitations and Challenges in the Stability of Cysteamine Eye Drop Compounded Formulations
    (Pharmaceuticals, 2022) Martín Sabroso, Cristina; Alonso González, Mario; Fernández Carballido, Ana María; Aparicio Blanco, Juan; Córdoba Díaz, Damián; Navarro García, Federico; Córdoba Díaz, Manuel; Torres Suárez, Ana Isabel
    Accumulation of cystine crystals in the cornea of patients suffering from cystinosis is considered pathognomonic and can lead to severe ocular complications. Cysteamine eye drop compounded formulations, commonly prepared by hospital pharmacy services, are meant to diminish the build-up of corneal cystine crystals. The objective of this work was to analyze whether the shelf life proposed for six formulations prepared following different protocols used in hospital pharmacies is adequate to guarantee the quality and efficacy of cysteamine eye drops. The long-term and in-use stabilities of these preparations were studied using different parameters: content of cysteamine and its main degradation product cystamine; appearance, color and odor; pH and viscosity; and microbiological analysis. The results obtained show that degradation of cysteamine was between 20% and 50% after one month of storage in the long-term stability study and between 35% and 60% in the in-use study. These data confirm that cysteamine is a very unstable molecule in aqueous solution, the presence of oxygen being the main degradation factor. Saturation with nitrogen gas of the solutions offers a means of reducing cysteamine degradation. Overall, all the formulae studied presented high instability at the end of their shelf life, suggesting that their clinical efficacy might be dramatically compromised.